Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Part D Becomes a Force in the Pharma Market

This article was originally published in RPM Report

You may also be interested in...



The Triumph of Part D

The US prescription drug market remains anemic, but don't blame the federal government. The Medicare Prescription Drug Benefit that began in 2006 is the only reason there has been any growth in the retail sector. No wonder industry is so eager for health care reform.

Medicare Part D "Downpayment": Coverage Gap Relief Added To Senate Health Reform Bill

Senate compromise attempts to meet in the middle by offering additional donut hole relief without using Part D dual-eligible rebates to pay for closing the coverage gap altogether.

MedPAC On Steroids: The Implications of a New Medicare Advisory Council

The creation of an independent health council to weigh in on Medicare reimbursement rates may be part of a final health reform bill. The idea has a number of implications for biopharma-good and bad.

Related Content

Topics

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel